1. Market Research
  2. > Healthcare
  3. > Medical Device
  4. > In Vitro Diagnostics Market Trends

Vital Signs - Strategies beyond BRIC: An Update on the African In Vitro Diagnostics Market

  • November 2013
  • 7 pages
  • Frost & Sullivan
Report ID: 1902013

Summary

Table of Contents

This issue of Vital Signs, released on November 22, 2013, provides overview of global IVD market dynamics, discuss growth strategy, and explore early opportunities in the African IVD market. Additionally, a company spotlight is provided for Global BioDiagnostics based in Temple, Texas. The company is focused on developing affordable diagnostic tests with the mission to improve global health and have developed a point-of-care diagnostic for tuberculosis.

Strategies Beyond BRIC: An Update on the African In Vitro Diagnostics Market

The in vitro diagnostics (IVD) market is transitioning from one that is cost-sensitive to one that is fully cost-constrained. It used to be that diagnostic tests received the fewest healthcare dollars amongst care providers, but with healthcare reforms in the United States and Europe causing restraints on procedural reimbursements, providers across the board are seeing fewer dollars. The IVD industry in established markets is also facing reduced laboratory budgets due to the sluggish economy and customer consolidation as a result of hospital and laboratory mergers. Essentially, the IVD industry needs to accustom to a much lower baseline of healthcare spending in the United States and other established markets. To successfully compete in challenging market dynamics, a critical strategy will be to identify and capture underpenetrated markets such as the emerging markets of Brazil, Russia, India, China (BRIC) and beyond. This article will provide an overview of global IVD market dynamics, discuss growth strategy, and explore early opportunities in the African IVD market.

Global IVD Overview: CEO Version

IVD will be a $51 billion market worldwide in 2013 and is forecast to grow at least 7% annually through 2017. IVD tests are performed on specimens like blood, tissue or urine, and testing is conducted in clinical settings. In the United States, for example, hospitals are the largest consumer of IVD products, or about 60% of IVD sales. The next largest customer segment is independent laboratories, with 34%, followed by physician office laboratories at only 7% of IVD sales. Customer segments will vary considerably by region.

Relative to other healthcare industries like medical device and pharmaceuticals, IVD market revenues are small. To compare, the medical device industry generated $364 billion this year, or about seven times that of IVD. The pharmaceutical industry generated about $1 trillion this year, or almost 20 times that of IVD, but is growing only 3-4%. IVD growth is keeping pace with that of the medical device industry. The large sizes of the medical device and pharmaceutical industries also represent large cost burdens to the healthcare system. Not only is IVD a smaller cost burden, it also has significant potential in reducing healthcare costs and, therefore, will have an important role in the future of healthcare.

Diagnostic test volumes are the guiding principles in assessing IVD market segments. Test volume is driven by test utilization, which is greatly impacted by healthcare access. IVD has a bright market outlook since the valuation of diagnostic tests is improving, such as in the case of companion diagnostics, which are essential to appropriate use of targeted therapies. Furthermore, there is growing demand for advanced technologies, as evidenced by the success of molecular diagnostics and the rapid uptake of clinical next-generation sequencing.

Global IVD includes immunochemistry, point-of-care testing (POCT), self-monitoring of blood glucose (SMBG), molecular diagnostics, clinical microbiology, coagulation, hematology, and tissue diagnostics segments. Market segmentation is largely driven by platform or functional space in the laboratory rather than disease or specimen type. Two segments, immunoassay and molecular diagnostics, exhibit unique market trends. The immunoassay segment includes product revenues of immunoassay and clinical chemistry, and is notable due to its large segment size of more than $18 billion globally and impressive growth trajectory. In previous years, immunochemistry had been driven by the sheer volume of immunoassay and clinical chemistry tests that were performed in established markets—these are routine tests in a highly automated area of the laboratory. New Frost & Sullivan research finds that presently and in the future, the immunoassay segment is more and more driven by growing demand for automated analyzers in China and other emerging markets. Molecular diagnostics is also remarkable because it is the fastest growing segment, at more than 12% annually. Nucleic acid analysis in diagnostic testing has only entered patient health relatively recently. According to Frost & Sullivan forecasts, the molecular diagnostics segment will be comparable to the size of the POCT segment within three years.

The top competitors by market share, or Tier I companies, include Roche Diagnostics, Siemens Healthcare, Abbott Laboratories, Ortho Clinical Diagnostics (J&J), and Beckman Coulter-Danaher. Tier II companies include Alere, a market leader in POCT; Bayer Diabetes Care, a player in the very large SMBG segment; bioMerieux, the leader in clinical microbiology; and others. While Tier I companies are global conglomerates, Tier II companies compete through laboratory specialization. When comparing market share breakout from 2009 to 2012, we see the industry consolidating in just a three-year time span. It is becoming more challenging for a company to survive if it is not a Tier I or II player. Frost & Sullivan expects continuing consolidation with future M&A guided by gaining access to new regions and customer segments.

Business models in IVD are also shifting to reflect the changing approach to health. As a nation, the United States has determined that sick patients are very expensive to care for. One aspect of controlling escalating healthcare costs is a new care model that includes sickness prevention and wellness goals. Consequently, the size of impacted populations and thus the addressable market expands as we increase touch points across the continuum of care, which is sure to appeal to IVD competitors.

Global Growth Strategies in the Tissue Diagnostics Segment

The tissue diagnostics segment has faced daunting market challenges for many years. The tissue diagnostics segment is $2.5 billion worldwide and is growing at 7.2% annually. There are five primary market participants that control 87% of the market. The top three have been acquired by very large companies: Ventana by Roche, Leica by Danaher, and Dako by Agilent. Tissue diagnostics is a mature market with a high degree of consolidation. Demand for automation has reached market saturation and there has been little technological change in platforms and products.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

2017 POC/Point-of-Care Testing Markets: Cancer Clinics, Ambulatory Centers, Surgery Centers, Nursing Homes, Birth Centers-- Volume and Sales Segment Forecasts, Emerging Technologies, Instrumentation Review, Competitive Strategies

  • $ 7500
  • Industry report
  • March 2017
  • by Venture Planning Group

This 1,007-page report provides a comprehensive analysis of the emerging POC market segments, including their dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, ...

IVD Market in BRIC by Product & Service, Technology, Application, Country - Forecast to 2022

  • $ 5650
  • Industry report
  • May 2017
  • by MarketsandMarkets

The IVD market in BRIC is expected to reach USD 15.71 billion by 2022 from USD 10.60 billion in 2017, at a CAGR of 8.2%. The key factors driving the growth of the market are growing patient awareness of ...

Microfluidics Market: Point of Care Testing Segment Anticipated to Register High Revenue Growth over the Forecast Period: Global Industry Analysis and Opportunity Assessment 2016–2026

  • $ 5000
  • Industry report
  • February 2017
  • by Future Market Insight Global & Consulting Pvt Ltd

With 14.5% CAGR, point of care testing segment is the largest segment among the global microfluidics market application segments By the end of 2026, the point of care testing segment is projected to reach ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.